Phase Ib/Ii Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma with PDL1 <50%

2023-508477-87-00 Phase I and Phase II (Integrated) - Other Ongoing, recruiting

Start 24 Jul 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites

Overview

Sponsor-declared trial summary

Phase Phase I and Phase II (Integrated) - Other
Status Ongoing, recruiting
Participants planned 102
Countries 1
Sites 1

Patients with localy advanced or metastatic non squamous non small cell lung cancer with PDL1˂50%.

Key facts

Sponsor
Centr Georges Francois Leclerc
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
24 Jul 2024 → ongoing
Decision date (initial)
2024-03-04
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with localy advanced or metastatic non squamous non small cell lung cancer with PDL1˂50%.

VersionLevelCodeTermSystem organ class
20.0 LLT 10079440 Non-squamous non-small cell lung cancer 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centr Georges Francois Leclerc

Sponsor organisation
Centr Georges Francois Leclerc
Address
1 Rue Professeur Marion
City
Dijon
Postcode
21000
Country
France

Scientific contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Head of project

Public contact point

Organisation
Centr Georges Francois Leclerc
Contact name
Head of project

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ongoing, recruiting 102 1
Rest of world 0

Investigational sites

France

1 site · Ongoing, recruiting
Centr Georges Francois Leclerc
Medical oncologie, 1 Rue Professeur Marion, 21000, Dijon

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2024-07-24 2024-07-25

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-11-03 France Acceptable
2024-03-04
2024-03-04
2 SUBSTANTIAL MODIFICATION SM-1 2025-01-17 France Acceptable
2025-02-12
2025-03-21
3 SUBSTANTIAL MODIFICATION SM-2 2025-05-26 France Acceptable
2025-06-20
2025-06-20
4 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-05 France Acceptable
2025-06-20
2025-12-05